Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT04862663
Recruiting
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/12/2025
Locations: Research Site, Tucson, Arizona +279 locations
Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
Register for Updates
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149
Recruiting
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +334 locations
Conditions: Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Register for Updates
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
NCT03425526
Recruiting
This phase I trial studies the side effects of allogeneic adenovirus-specific cytotoxic T lymphocytes (donor T cell therapy) and to see how well they work in treating patients with a weakened immune system (immunocompromised) and adenovirus-related disease. Allogeneic adenovirus-specific cytotoxic T lymphocytes are made from donated blood cells grown in the laboratory and are designed to kill viruses that can cause infections in immunocompromised patients with adenovirus-related disease.
Gender:
ALL
Ages:
All
Trial Updated:
08/12/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Immunocompromised
Register for Updates
Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx
NCT04667585
Recruiting
The purpose of this study is to use intra-treatment 18FDG-PET/CT during definitive radiation therapy for human papillomavirus (HPV)-related oropharyngeal cancer (OPC) as an imaging biomarker to identify and select patients with a favorable response for chemoradiation dose de-escalation. This study will prospectively evaluate the clinical outcomes for patients undergoing dose de-escalation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Duke University Medical Center, Durham, North Carolina +1 locations
Conditions: Oropharynx Cancer
Register for Updates
Behavioral and Neural Representations of Subjective Effort Cost
NCT04041154
Recruiting
The goal of this proposal is to understand the common and distinct behavioral and neural representations of subjective effort valuation, and how these representations are influenced by fatigue and changes in motivation. It is hypothesized that the brain will use overlapping and distinct neural circuits to represent cognitive and physical effort value, and that fatigue and enhanced motivation will influence the subjective value of effort.
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
08/12/2025
Locations: Kennedy Krieger Institute, Baltimore, Maryland
Conditions: Fatigue
Register for Updates
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
NCT04624230
Recruiting
This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US and EU, patients with prior TNFi failure or intolerance will be enrolled. Outside of the US or EU, patients having had inadequate response or intolerance to oral or IV corticosteroids or azathioprine or 6-mercaptopurine or TNFi will be enrolled. All eligible participants will initially receive open label tofacitinib... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
08/12/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +76 locations
Conditions: Ulcerative Colitis
Register for Updates
Quantitative MRI for Myelofibrosis
NCT01973881
Recruiting
This study is for the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/12/2025
Locations: University of Michigan Hospital, Ann Arbor, Michigan
Conditions: Myelofibrosis
Register for Updates
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965
Recruiting
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells. HER2-negative describes cells that have a small amount or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Highlands Oncology Group, PA, Fayetteville, Arkansas +7 locations
Conditions: Breast Cancer
Register for Updates
The Effect of Multimodal Pain Regimen on Use of Narcotics After Rotator Cuff Tear Repair
NCT07076069
Recruiting
The goal of this clinical trial is to understand which group of pain control medications work best in adults after rotator cuff surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Montefiore Hutchinson Campus, Bronx, New York
Conditions: Rotator Cuff Repairs, Pain Management
Register for Updates
Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction
NCT07108660
Recruiting
Prospective, multi-center, cluster-randomized trial of a hospital Infection Preventionist (IP)-led quality improvement study to provide clinical teams with just-in-time clinical education and reinforcement of existing best practices recommendations based on the output of a possible Central Line Associated Blood Stream Infection (CLABSI) Machine Learning (ML) prediction model. The objective is to determine whether providing this model to Infection Preventionists will decrease the CLABSI rates ve... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Providence Alaska Medical Center, Anchorage, Alaska +18 locations
Conditions: Central Line Associated Blood Stream Infections (CLABSI)
Register for Updates
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
NCT07100782
Recruiting
The purpose of this study is to better understand how hormone suppression with Relugolix Combination-Therapy (CT) affects pelvic pain, inflammation, and pain sensitivity in women with moderate-to-severe endometriosis associated pelvic pain.
Gender:
FEMALE
Ages:
Between 21 years and 49 years
Trial Updated:
08/12/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Endometriosis, Pelvic Pain
Register for Updates
A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear
NCT07054606
Recruiting
Assess the impact of concomitant Miebo use while wearing contact lenses
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: Site 101, San Diego, California +7 locations
Conditions: Dry Eye
Register for Updates